In vivo MRI of early stage mammary cancers and the normal mouse mammary gland

NMR in Biomedicine

Volumn 24, Issue 7, 2011, Pages 880-887

  Jansen, Sanaz A ^a,b   Conzen, Suzanne D ^a   Fan, Xiaobing ^a   Markiewicz, Erica ^a   Krausz, Thomas ^a   Newstead, Gillian M ^a   Karczmar, Gregory S ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Ductal carcinoma in situ; Imaging; Mammary gland; Mammary intraepithelial neoplasia; Mouse models; MRI

Indexed keywords

BENIGN LESION; BREAST CANCER; DUCTAL CARCINOMA IN SITU; EARLY DETECTION; FAT SUPPRESSION; GRADIENT RECALLED ECHOS; HIGH RESOLUTION; HIGH SENSITIVITY; HIGH-RESOLUTION IMAGING; IMAGE CONTRASTS; IN-SITU; IN-VIVO; INVASIVE TUMORS; LYMPH NODE; MAMMARY CANCER; MAMMARY GLAND; MAMMARY INTRAEPITHELIAL NEOPLASIA; MAMMARY TISSUE; MOUSE MODELS; MULTI SLICES; NORMAL TISSUE; PATIENT MANAGEMENT; SIGNAL TO NOISE; SMALL SIZE; TRANSGENIC MICE; TRANSGENIC MODELS; TWO-STEP PROCESS; WILD TYPES;

DISEASE CONTROL; DISEASES; GENETIC ENGINEERING; IMAGING TECHNIQUES; RATING; SIGNAL TO NOISE RATIO; TISSUE;

MAMMALS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER SIZE; CANCER STAGING; EARLY CANCER; FEASIBILITY STUDY; FEMALE; IN VIVO STUDY; INTRADUCTAL CARCINOMA; LYMPH NODE; MOUSE; MUSCLE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRECANCER; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SIGNAL NOISE RATIO; TRANSGENIC MOUSE; WILD TYPE;

ANIMALS; BREAST NEOPLASMS; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MAMMARY GLANDS, ANIMAL; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, TRANSGENIC;

MUS; MUS MUSCULUS;

EID: 80051596153     PISSN: 09523480     EISSN: 10991492     Source Type: Journal    
DOI: 10.1002/nbm.1643     Document Type: Article

References (31)

1. Altekruse SF, Kosary CL, Krapcho M, Neyman N, Aminou RWW, Ruhl J, Howlader N, Tatalovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR, Cronin K, Chen HS, Feuer EJ, Stinchcomb DG, Edwards BK. SEER Cancer Statistics Review, 1975-2007. National Cancer Institute: Bethesda, MD, 2009.
2. American Cancer Society. Breast Cancer Facts & Figures 2009-2010. American Cancer Society, Inc.
3. Gloeckler Ries LA, Reichman ME, Lewis DR, Hankey BF, Edwards BK. Cancer survival and incidence from the Surveillance, Epidemiology, and End Results (SEER) program. Oncologist 2003; 8: 541-552.
4. Benson JR, Jatoi I, Keisch M, Esteva FJ, Makris A, Jordan VC. Early breast cancer. Lancet 2009; 373: 1463-1479.
5. Allegra CJ, Aberle DR, Ganschow P, Hahn SM, Lee CN, Millon-Underwood S, Pike MC, Reed SD, Saftlas AF, Scarvalone SA, Schwartz AM, Slomski C, Yothers G, Zon R. National Institutes of Health State-of-the-Science Conference statement: diagnosis and management of ductal carcinoma in situ. J. Natl. Cancer Inst. 2009; 102: 161-169.
6. Erbas B, Provenzano E, Armes J, Gertig D. The natural history of ductal carcinoma in situ of the breast: a review. Breast Cancer Res. Treat. 2006; 97: 135-144.
7. Dowsett M, Goldhirsch A, Hayes DF, Senn HJ, Wood W, Viale G. International Web-based consultation on priorities for translational breast cancer research. Breast Cancer Res. 2007; 9: R81.
8. Thompson A, Brennan K, Cox A, Gee J, Harcourt D, Harris A, Harvie M, Holen I, Howell A, Nicholson R, Steel M, Streuli C. Evaluation of the current knowledge limitations in breast cancer research: a gap analysis. Breast Cancer Res. 2008; 10: R26.
9. Llombart-Cussac A. Improving decision-making in early breast cancer: who to treat and how? Breast Cancer Res. Treat. 2008; 112 (Suppl 1): 15-24.
10. Pawitan Y, Bjohle J, Amler L, Borg AL, Egyhazi S, Hall P, Han X, Holmberg L, Huang F, Klaar S, Liu ET, Miller L, Nordgren H, Ploner A, Sandelin K, Shaw PM, Smeds J, Skoog L, Wedren S, Bergh J. Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts. Breast Cancer Res. 2005; 7: R953-964.
11. Bedard PL, Di Leo A, Piccart-Gebhart MJ. Taxanes: optimizing adjuvant chemotherapy for early-stage breast cancer. Nat. Rev. Clin. Oncol. 2010; 7: 22-36.
12. Kesisis G, Makris A, Miles D. Update on the use of aromatase inhibitors in early-stage breast cancer. Breast Cancer Res. 2009; 11: 211.
13. Dey JH, Bianchi F, Voshol J, Bonenfant D, Oakeley EJ, Hynes NE. Targeting fibroblast growth factor receptors blocks PI3K/AKT signaling, induces apoptosis, and impairs mammary tumor outgrowth and metastasis. Cancer Res. 2010; 70: 4151-4162.
14. Lu Y, Bertran S, Samuels TA, Mira YLR, Farias EF. Mechanism of inhibition of MMTV-neu and MMTV-wnt1 induced mammary oncogenesis by RARalpha agonist AM580. Oncogene 2010; 29: 3665-3676.
15. Abbey CK, Borowsky AD, Gregg JP, Cardiff RD, Cherry SR. Preclinical imaging of mammary intraepithelial neoplasia with positron emission tomography. J. Mammary Gland. Biol. Neoplasia 2006; 11: 137-149.
16. Abbey CK, Borowsky AD, McGoldrick ET, Gregg JP, Maglione JE, Cardiff RD, Cherry SR. In vivo positron-emission tomography imaging of progression and transformation in a mouse model of mammary neoplasia. Proc. Natl. Acad. Sci. U.S.A. 2004; 101: 11438-11443.
17. Jansen SA, Conzen SD, Fan X, Krausz T, Zamora M, Foxley S, River J, Newstead GM, Karczmar GS. Detection of in situ mammary cancer in a transgenic mouse model: in vitro and in vivo MRI studies demonstrate histopathologic correlation. Phys. Med. Biol. 2008; 53: 5481-5493.
18. Maroulakou IG, Anver M, Garrett L, Green JE. Prostate and mammary adenocarcinoma in transgenic mice carrying a rat C3(1) simian virus 40 large tumor antigen fusion gene. Proc. Natl. Acad. Sci. U.S.A. 1994; 91: 11236-11240.
19. Cardiff RD, Anver MR, Gusterson BA, Hennighausen L, Jensen RA, Merino MJ, Rehm S, Russo J, Tavassoli FA, Wakefield LM, Ward JM, Green JE. The mammary pathology of genetically engineered mice: the consensus report and recommendations from the Annapolis meeting. Oncogene 2000; 19: 968-988.
20. Green JE, Shibata MA, Yoshidome K, Liu ML, Jorcyk C, Anver MR, Wigginton J, Wiltrout R, Shibata E, Kaczmarczyk S, Wang W, Liu ZY, Calvo A, Couldrey C. The C3(1)/SV40 T-antigen transgenic mouse model of mammary cancer: ductal epithelial cell targeting with multistage progression to carcinoma. Oncogene 2000; 19: 1020-1027.
21. Frech MS, Halama ED, Tilli MT, Singh B, Gunther EJ, Chodosh LA, Flaws JA, Furth PA. Deregulated estrogen receptor alpha expression in mammary epithelial cells of transgenic mice results in the development of ductal carcinoma in situ. Cancer Res. 2005; 65: 681-685.
22. Cardiff RD. Mammary Cancer in Humans and Mice: A Tutorial for Comparative Pathology, Date accessed: December 30, 2010.
23. Jansen SA, Conzen SD, Fan X, Markiewicz EJ, Newstead GM, Karczmar GS. Magnetic resonance imaging of the natural history of in situ mammary neoplasia in transgenic mice: a pilot study. Breast Cancer Res. 2009; 11: R65.
24. Green JE, Shibata MA, Shibata E, Moon RC, Anver MR, Kelloff G, Lubet R. 2-difluoromethylornithine and dehydroepiandrosterone inhibit mammary tumor progression but not mammary or prostate tumor initiation in C3(1)/SV40 T/t-antigen transgenic mice. Cancer Res. 2001; 61: 7449-7455.
25. Fan X, Markiewicz EJ, Zamora M, Karczmar GS, Roman BB. Comparison and evaluation of mouse cardiac MRI acquired with open birdcage, single loop surface and volume birdcage coils. Phys. Med. Biol. 2006; 51: N451-459.
26. Jansen SA, Paunesku T, Fan X, Woloschak GE, Vogt S, Conzen SD, Krausz T, Newstead GM, Karczmar GS. Ductal carcinoma in situ: X-ray fluorescence microscopy and dynamic contrast-enhanced MR imaging reveals gadolinium uptake within neoplastic mammary ducts in a murine model. Radiology 2009; 253: 399-406.
27. Bolander FF Jr. Differential characteristics of the thoracic and abdominal mammary glands from mice. Exp. Cell. Res. 1990; 189: 142-144.
28. Sheldon WG, Owen K, Weed L, Kodell R. Distribution of mammary gland neoplasms and factors influencing metastases in hybrid mice. Lab. Anim. Sci. 1982; 32: 166-168.
29. Naylor MJ, Ormandy CJ. Mouse strain-specific patterns of mammary epithelial ductal side branching are elicited by stromal factors. Dev. Dyn. 2002; 225: 100-105.
30. Cardiff RD, Wellings SR. The comparative pathology of human and mouse mammary glands. J. Mammary Gland. Biol. Neoplasia 1999; 4: 105-122.
31. Schnall MD, Blume J, Bluemke DA, DeAngelis GA, DeBruhl N, Harms S, Heywang-Kobrunner SH, Hylton N, Kuhl CK, Pisano ED, Causer P, Schnitt SJ, Thickman D, Stelling CB, Weatherall PT, Lehman C, Gatsonis CA. Diagnostic architectural and dynamic features at breast MR imaging: multicenter study. Radiology 2006; 238: 42-53.